Oramed Pharmaceuticals GAAP EPS of $1.26

* Oramed Pharmaceuticals press release [https://seekingalpha.com/pr/20309770-oramed-reports-fiscal-third-quarter-2025-financial-results] (ORMP [https://seekingalpha.com/symbol/ORMP]): nine-month period 2025 GAAP EPS of $1.26.
* Robust balance sheet growth: Total assets increased 42% from $155.3 million to $220.5 million year-over-year.
* Operating expenses: R&D expenses decreased from $4.9 million to $4.4 million; G&A expenses increased from $4.3 million to $5.0 million.

MORE ON ORAMED PHARMACEUTICALS

* Seeking Alpha’s Quant Rating on Oramed Pharmaceuticals [https://seekingalpha.com/symbol/ORMP/ratings/quant-ratings]
* Historical earnings data for Oramed Pharmaceuticals [https://seekingalpha.com/symbol/ORMP/earnings]
* Financial information for Oramed Pharmaceuticals [https://seekingalpha.com/symbol/ORMP/income-statement]